Xlife Sciences AG

Xlife Sciences AG focuses on the development and commercialization of technologies in the life sciences industry. The company's project consists of technology platforms that focuses to identify new therapeutic approaches and biomarkers for common diseases based on human genetic data; focuses on functional screening of antibodies by microfluidics-based technologies; and provides services for drug development. It also develops mono-and bispecific anti-tumor antibodies for the treatment of life-threatening diseases, with a focus on orphan hematopoietic malignancies; researches, develops, and manufactures chemical and active pharmaceutical ingredients for human and veterinary medicine; and develops new methods for the early identification of kidney diseases. In addition, the company develops and implements projects for cellular 3D screen printing of biomaterials for medical and biotechnological sector; new drug delivery system for the controlled release of pharmaceutical actives; and Neuromex, a screening instrument for the early-stage detection of neurodegenerative diseases, as well as supplies circular systems for complex medical devices. Further, it develops artificial intelligence-based computer-assisted diagnostic systems for medical professionals. The company is based in Zurich, Switzerland. Show More...